In a recent study on the importance of triggering IFN-γ signaling for sensitizing cells to ICIs, avadomide, a cereblon E3 ligase modulator, stimulated a feedforward cascade of revigorated T cell responses by inducing type Ι and II IFN-γ signaling in chronic lymphocytic leukemia (CLL) patients, thus leading to CD8 T cell-inflamed tumor microenvironments that responded to anti-PD-1/PD-L1 therapy (Ioannou et al., 2021). This evidence concerns the gene PDCD1 and B-cell chronic lymphocytic leukemia.